Novavax, Inc.
NVAX
$9.06
-$0.29-3.10%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | -52.48% | 64.69% | 20.27% | 9.22% | 25.92% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -52.48% | 64.69% | 20.27% | 9.22% | 25.92% |
| Cost of Revenue | -20.21% | -31.95% | -35.46% | -37.58% | -39.23% |
| Gross Profit | -77.01% | 793.45% | 233.49% | 178.13% | 580.35% |
| SG&A Expenses | -56.33% | -51.77% | -54.90% | -49.97% | -34.24% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -32.81% | -38.71% | -44.88% | -44.06% | -39.45% |
| Operating Income | -91.20% | 342.85% | 243.72% | 228.18% | 211.92% |
| Income Before Tax | -117.64% | 350.36% | 225.36% | 249.33% | 223.49% |
| Income Tax Expenses | -83.20% | -82.86% | 74.47% | 56.89% | 215.82% |
| Earnings from Continuing Operations | -118.35% | 334.83% | 219.97% | 243.65% | 220.06% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -118.35% | 334.83% | 219.97% | 243.65% | 220.06% |
| EBIT | -91.20% | 342.85% | 243.72% | 228.18% | 211.92% |
| EBITDA | -87.27% | 422.10% | 285.75% | 269.48% | 240.20% |
| EPS Basic | -117.68% | 323.82% | 198.38% | 198.02% | 198.04% |
| Normalized Basic EPS | -86.46% | 366.55% | 232.43% | 194.50% | 199.26% |
| EPS Diluted | -121.94% | 281.67% | 179.33% | 182.58% | 183.78% |
| Normalized Diluted EPS | -86.69% | 320.85% | 208.54% | 176.99% | 181.47% |
| Average Basic Shares Outstanding | 3.25% | 6.47% | 12.87% | 24.83% | 37.98% |
| Average Diluted Shares Outstanding | 0.64% | 8.99% | 14.92% | 26.69% | 40.90% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |